Fig. 7
From: Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines
Oncolytic effect of CV-B3/2035A on ex vivo patient-derived endometrioid adenocarcinoma samples. Five endometrioid adenocarcinoma samples (EC; Case 1–5) and two normal endometrium samples (Case 6–7) were divided into ∼1-mm3 pieces and treated with CV-B3/2035A (1 × 106 TCID50) or left untreated (n = 4 per group). After 72 h, a tissue viability was assessed using a modified HDRA method and b replication of CV-B3/2035A in both tumor and normal tissue samples was evaluated by qRT-PCR